PULMATRIX, INC. Deferred Federal Income Tax Expense (Benefit)
PULMATRIX, INC. (PULM) reported Deferred Federal Income Tax Expense (Benefit) of -$2.36 million for the 12-month period ending 2016-12-31, per its 10-K filed 2018-03-13.
Discontinued › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2018-03-13
- PULMATRIX, INC. deferred federal income tax expense (benefit) for fiscal 2016 was -$2.36M.
- PULMATRIX, INC. deferred federal income tax expense (benefit) for fiscal 2015 was -$1.75M.
- PULMATRIX, INC. deferred federal income tax expense (benefit) for fiscal 2014 was -$1.03M.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month |
|---|---|
| 2016-12-31 | -$2.36M 10-K · filed 2018-03-13 |
| 2015-03-31 | -$1.75M 10-K · filed 2015-06-10 |
| 2014-03-31 | -$1.03M 10-K · filed 2015-06-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |